|
2025 Conference Publication Risk factors for dose-limiting, chronic and severe chemotherapy-induced peripheral neuropathyLi, Tiffany, Timmins, Hannah C., Horvath, Lisa G., Harrison, Michelle, Grimison, Peter, Friedlander, Michael, Marx, Gavin, Boyle, Frances, Wyld, David, Henderson, Robert, King, Tracy, Baron-Hay, Sally, Kiernan, Matthew C., Barnes, Elizabeth H., Goldstein, David and Park, Susanna B. (2025). Risk factors for dose-limiting, chronic and severe chemotherapy-induced peripheral neuropathy. Australian and New Zealand Association of Neurologists Clinical Neurophysiology Workshop, Gold Coast, QLD, Australia, 6-9 October 2024. Shannon, Ireland: Elsevier. doi: 10.1016/j.clinph.2025.2110921 |
|
2025 Conference Publication Phase Ib/IIa dose escalation and expansion study of 212Pb-ADVC001 in metastatic castration-resistant prostate cancer (mCRPC): TheraPb-Phase I/II Trial in ProgressGoh, Jeffrey, Pattison, David, Ngai, Stanley, Katchel, Loren, Holmes, Ingrid, Baker, Sean, Biggs, Heather, Cuscaden, Claire, Campbell, Louise, Brady, Jasmine, Lindsay, Karen, Latter, Melissa, Griffiths, Matthew, O'Mahoney, Eoin, Dhiantravan, Nattakorn, Francis, Roslyn, Rose, Stephen, Soderholm, Amelia, Baronet, Meghan, Crumbaker, Megan, Kryza, Thomas, Shakti, Stelle, Naidoo, Sheruna, Puttick, Simon, Horsfall, Aimee, Barkhausen, Christoph, Kuan, Kevin, Santoro, Paola, Skingley, Lesley ... Hansen, Aaron (2025). Phase Ib/IIa dose escalation and expansion study of 212Pb-ADVC001 in metastatic castration-resistant prostate cancer (mCRPC): TheraPb-Phase I/II Trial in Progress. HOBOKEN: WILEY. |
|
2025 Journal Article How to Support Participants in Urogenital and Prostate Clinical Trials: A Qualitative PerspectiveRoberts, Natasha A., Davis, Ian D., Wyld, David, Goh, Jeffrey, Thompson, Maxwell, Gedye, Craig and Dhillon, Haryana M. (2025). How to Support Participants in Urogenital and Prostate Clinical Trials: A Qualitative Perspective. Psycho-Oncology, 34 (7) e70214, 7. doi: 10.1002/pon.70214 |
|
2025 Journal Article Peptide receptor radionuclide therapy in malignant insulinomaPattison, David A., Kong, Grace, Akhurst, Timothy, Burge, Matthew, Chiang, Cherie, Hofman, Michael S., Hung, Te-Jui, Love, Amanda, Michael, Michael, Okano, Satomi, Ravi Kumar, Aravind S., Sachithanandan, Nirupa, Wyld, David and Hicks, Rodney J. (2025). Peptide receptor radionuclide therapy in malignant insulinoma. Endocrine-Related Cancer, 32 (6) e250018, 6. doi: 10.1530/erc-25-0018 |
|
2025 Journal Article Factors that influence clinical trial participation for oncology patients in Australia: a scoping reviewYou, Kyung Ha, Lwin, Zarnie, Ahern, Elizabeth, Wyld, David and Roberts, Natasha (2025). Factors that influence clinical trial participation for oncology patients in Australia: a scoping review. BMJ Open, 15 (6) e095355, 1-11. doi: 10.1136/bmjopen-2024-095355 |
|
2025 Conference Publication Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumoursBurge, Matthew E., Wyld, David, Pattison, David A., Bahamad, Sandra, Hayes, Sarah J., Kuszewski, Julia A., Chantrill, Lorraine A., Price, Timothy Jay, Wong, Hui-Li, Chan, David, Grover, Piyush, Michael, Michael, Siu, Derrick, Bishop, Christine, Barker, Daniel, Goodwin, Rachel Anne, O'Callaghan, Christopher J., Loree, Jonathan M. and Mak, W. John (2025). Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomized study of cessation of somatostatin analogues (SSA) after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours. 2025 ASCO Annual Meeting, Chicago, IL United States, 30 May - 3 June 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.16_suppl.tps4224 |
|
2025 Journal Article Institutional factors associated with equitable cancer care provision for culturally and linguistically diverse populations in Queensland, Australia: a critical race theory analysisScanlon, Brighid, Roberts, Natasha, Wyld, David, Toloo, Ghasem Sam and Durham, Jo (2025). Institutional factors associated with equitable cancer care provision for culturally and linguistically diverse populations in Queensland, Australia: a critical race theory analysis. Journal of Racial and Ethnic Health Disparities, 1-15. doi: 10.1007/s40615-025-02477-8 |
|
2025 Conference Publication An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs)Mak, Blossom, Tran, Ben, Thomas, Hayley, Pashankar, Farzana D., Hansen, Aaron Richard, Feldman, Darren R., Huddart, Robert A, Wheater, Matthew, Dunwoodie, Elaine, Mazhar, Danish, Lawrence, Nicola Jane, Stevanovic, Amanda Gwendolyn, Birtle, Alison Jane, Oladipo, Olabode, Wyld, David, Balagtas, Jay Michael S., Stockler, Martin R., Grimison, Peter S. and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs). 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 13-15 February 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.5_suppl.tps653 |
|
2025 Conference Publication Phase Ib/IIa dose escalation and expansion study of [ 212 Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II studyHansen, Aaron Richard, Pattison, David A., Ngai, Stanley, Karmann, Anna, Walker, Amanda J., Campbell, Louise, Brady, Jasmine, Katchel, Loren, Holmes, Ingrid, Rose, Stephen E., Baronet, Meghan C., Kryza, Thomas, Vito, Alyssa, Tieu, William, Kuan, Kevin, Griffiths, Matthew R., O’Mahoney, Eoin, Latter, Melissa, Gan, Chun Loo Loo and Wyld, David (2025). Phase Ib/IIa dose escalation and expansion study of [ 212 Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II study. 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 13-15 February 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.5_suppl.tps275 |
|
2024 Conference Publication Patient reported measures as the optimal assessment of chemotherapy-induced peripheral neuropathyLi, Tiffany, Timmins, Hannah C., Mahfouz, Fawaz M., Trinh, Terry, Mizrahi, David, Horvath, Lisa G., Harrison, Michelle, Grimison, Peter, Friedlander, Michael, Marx, Gavin, Boyle, Frances, Wyld, David, Henderson, Robert, King, Tracy, Baron-Hay, Sally, Kiernan, Matthew C., Rutherford, Claudia, Goldstein, David and Park, Susanna B. (2024). Patient reported measures as the optimal assessment of chemotherapy-induced peripheral neuropathy. COSA's 51st Annual Scientific Meeting Bridging gaps, building progress, breaking down disparities, Gold Coast, QLD, Australia, 13 - 15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14116 |
|
2024 Conference Publication Clinical risk factors associated with development of significant nerve damage during chemotherapyLi, Tiffany, Timmins, Hannah C., Horvath, Lisa G., Harrison, Michelle, Grimison, Peter, Friedlander, Michael, Marx, Gavin, Boyle, Frances, Wyld, David, Henderson, Robert, Baron-Hay, Sally, Kiernan, Matthew C., Barnes, Elizabeth H., Goldstein, David and Park, Susanna B. (2024). Clinical risk factors associated with development of significant nerve damage during chemotherapy. COSA's 51st Annual Scientific Meeting Bridging gaps, building progress, breaking down disparities, Gold Coast, QLD, Australia, 13 - 15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14117 |
|
2024 Conference Publication When good intentions are not enough: the development of the Equity ProcEss frameworK (EPEK) to promote equity in cancerScanlon, Brighid, Wyld, David, Durham, Jo, Toloo, Sam and Roberts, Natasha (2024). When good intentions are not enough: the development of the Equity ProcEss frameworK (EPEK) to promote equity in cancer. COSA's 51st Annual Scientific Meeting Bridging gaps, building progress, breaking down disparities, Gold Coast, QLD, Australia, 13 - 15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14116 |
|
2024 Journal Article Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)–protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancerWebb, Penelope M, Brown, Amy, Brown, Bena, Collins, Louisa G, Crawford Williams, Fiona, Doupain, Kerrie, Eastgate, Melissa, Fennelly, Vicki, Girgis, Afaf, Hartel, Gunter, Ladwa, Rahul, Martin, Karen, Mason, Robert, McGuire, Peter, Miller, Elizabeth, O’Brien, Suzanne, Packer, Rebecca, Pinkham, Mark B, Sabesan, Sabe, Sanmugarajah, Jasotha, Slapp, Georgia, Tapsall, Doreen, White, Jeanie, Wishart, Laurelie R, Wyld, David and Chan, Raymond J (2024). Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)–protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancer. BMJ Open, 14 (11) e090836, 1-10. doi: 10.1136/bmjopen-2024-090836 |
|
2024 Conference Publication "Signing up for the PRoCESS [Pancreatic cancer Relatives Counselling and Education Support Service] Trial was the most important thing I did as a carer"Beesley, Vanessa L., Roset, Natalie, Turner, Jane, Yates, Patsy, Wyld, David, Eastgate, Melissa, Chan, Raymond, Collins, Louisa, Stewart, Michelle, Beebe, Hanna, Malt, Maryrose, Kelly, Caroline and Neale, Rachel (2024). "Signing up for the PRoCESS [Pancreatic cancer Relatives Counselling and Education Support Service] Trial was the most important thing I did as a carer". COSA's 51st Annual Scientific Meeting: Bridging gaps, building progress, breaking down disparities, Gold Coast, QLD, Australia, 13 - 15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14116 |
|
2024 Journal Article Implementation of Patient-Reported Outcomes in a Medical Oncology Setting (the iPROMOS Study): type II hybrid implementation studyRoberts, Natasha Anne, Pelecanos, Anita, Alexander, Kimberly, Wyld, David and Janda, Monika (2024). Implementation of Patient-Reported Outcomes in a Medical Oncology Setting (the iPROMOS Study): type II hybrid implementation study. Journal of Medical Internet Research, 26 e55841, e55841. doi: 10.2196/55841 |
|
2024 Journal Article Validity of patient-reported outcome measures in evaluating nerve damage following chemotherapyLi, Tiffany, Timmins, Hannah C., Mahfouz, Fawaz M., Trinh, Terry, Mizrahi, David, Horvath, Lisa G., Harrison, Michelle, Grimison, Peter, Friedlander, Michael, Marx, Gavin, Boyle, Frances, Wyld, David, Henderson, Robert, King, Tracy, Baron-Hay, Sally, Kiernan, Matthew C., Rutherford, Claudia, Goldstein, David and Park, Susanna B. (2024). Validity of patient-reported outcome measures in evaluating nerve damage following chemotherapy. JAMA Network Open, 7 (8) e2424139, e2424139. doi: 10.1001/jamanetworkopen.2024.24139 |
|
2024 Conference Publication Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trialNalder, Mark, Kulasegaran, Tivya, Lundie, Ben, Woods, Rick, Eastgate, Melissa A., Wyld, David and Burge, Matthew E. (2024). Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trial. 2024 ASCO Annual Meeting, Chicago, IL, United States, 31 May–4 June 2024. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2024.42.16_suppl.12121 |
|
2024 Conference Publication Identifying optimized assessment of nerve damage during chemotherapyLi, Tiffany, Timmins, Hannah C, Mahfouz, Fawaz Mayez, Mizrahi, David, Horvath, Lisa, Harrison, Michelle L., Grimison, Peter S., Friedlander, Michael, Marx, Gavin M., Boyle, Frances M., Wyld, David, Henderson, Robert, King, Tracy, Baron-Hay, Sally E., Kiernan, Matthew C, Rutherford, Claudia, Goldstein, David and Park, Susanna B (2024). Identifying optimized assessment of nerve damage during chemotherapy. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.12016 |
|
2024 Journal Article Corrigendum to: COVID-19 vaccine hesitancy, acceptance and informational needs in an Australian cancer population: a cross-sectional surveyScanlon, Brighid, Wyld, David, Firman, Paul, Nakagaki, Midori, Durham, Jo, Kennedy, Glen, Moran, Paul, Smith, Michael, Button, Elise and Gavin, Nicole (2024). Corrigendum to: COVID-19 vaccine hesitancy, acceptance and informational needs in an Australian cancer population: a cross-sectional survey. Australian Health Review, 48 (3), 335-335. doi: 10.1071/ah22142_co |
|
2024 Journal Article Exploring unmet needs in prostate cancer care: a cross-sectional descriptive studyRoberts, Natasha A., Esler, Rachel, Pearce, Adam, Wyld, David, Smith, Michael, Woollett, Kaylene, Mazariego, Carolyn and Roberts, Matthew J. (2024). Exploring unmet needs in prostate cancer care: a cross-sectional descriptive study. European Urology Open Science, 62, 36-42. doi: 10.1016/j.euros.2024.01.018 |
